Anti-VEGF therapy: a new approach to colorectal cancer therapy.
The purpose of this review is to discuss the inhibition of vascular endothelial growth factor as a treatment for advanced colorectal cancer. The review will begin by summarizing the theory behind vascular endothelial growth factor inhibition and how this affects tumor angiogenesis. The major clinical trials that have examined antivascular endothelial growth factor agents to treat patients with advanced colorectal cancer will then be described. Finally, there is a commentary regarding the status of targeted agents currently in development for the treatment of advanced colorectal cancer and a discussion of the potential future considerations for the use of antivascular endothelial growth factor agents in clinical practice.
Carrato
Alfredo
A
Medical Oncology Service, Elche University Hospital, Department of Medicine, Miguel Hernandez University, Camino de la Almazara 11, Elche, 03203 Alicante, Spain. acarrato@telefonica.net
Gallego-Plazas
Javier
J
Guillen-Ponce
Carmen
C
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A